Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05782283 · ClinicalTrials.gov registry record · NA
A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 279
- Enrollment target
NCT05782283: Completed NA study, sponsored by Mayo Clinic.
NCT05782283 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 279 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05782283, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 279 participants
- Enrollment target
Study Summary
The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
Interventions
- DEVICE ACE (AI-Cirrhosis-ECG) 2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2025-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05782283
The ClinicalTrials.gov registry entry for NCT05782283 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACE (AI-Cirrhosis-ECG) 2.0 is the first listed.
NCT05782283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05782283 about?
NCT05782283 is a clinical study titled "A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram". The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
What is the current status of trial NCT05782283?
This trial is currently completed. It is a NA study. The enrollment target is 279 participants. The study started on 2023-04-18. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT05782283?
The interventions under investigation include: ACE (AI-Cirrhosis-ECG) 2.0 (DEVICE).
Who is sponsoring clinical trial NCT05782283?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.